Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Estrogen receptor β role in tumour suppression of triple negative breast cancer - ChIPseq experiment

ABSTRACT: Estrogen receptor β role in tumour suppression of triple negative breast cancer - ChIPseq experiment

PROVIDER: PRJEB33056 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3376640.fastq.gz	Fastqsanger.gz
	ERR3376637.fastq.gz	Fastqsanger.gz
	ERR3376638.fastq.gz	Fastqsanger.gz
	ERR3376639.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Estrogen receptor β role in tumour suppression of triple negative breast cancer - ChIPseq experiment

Project description:Breast cancer (BC) is the most common cancer in women worldwide, and is classified in multiple subtypes, including the so called triple-negative BC (TNBC). This is characterized by lack of estrogen receptor alpha (ERα), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2/neu), that represent common targets for BC treatment. Their absence limits the number of therapies that may be applied for TNBC treatment, suggesting the need to identify novel therapeutic targets against this disease. Several studies reported that the beta ER subtype (ERβ) is expressed in a sizeable fraction of TNBCs where its presence correlates with improved patient outcome. We evaluated ERβ expression in TNBC tissues by immunohistochemistry using two validated antibodies, demonstrating presence of this protein in 28% of samples. To investigate, in this context, the role of this estrogen receptor in TNBC biology, ERβ-expressing cell lines, representing different TNBC subtypes, were generated. Cellular and functional assays confirmed the antiproliferative activity of ERβ in TNBCs. Interaction proteomics revealed in BC nuclei the presence of several protein complexes associated with this receptor involved in chromatin remodeling, miRNA maturation and mRNA transcription. Transcriptome analyses pointed out tumor subtype-specific signaling pathways deregulation. Interestingly, among these the cholesterol biosynthesis pathway was commonly downregulated in all cell lines tested. Global analyses of ERβ binding to the genome showed its recruitment to regulatory sites of Sterol Regulatory Element-Binding Protein 1 (SREBP1), indicating a direct regulation of this pathway by the receptor. These findings suggest that drugs targeting components of cholesterol biosynthesis pathway may be new potential therapeutic options for TNBC treatment.

2019-12-02 | E-MTAB-8056 | biostudies-arrayexpress

Estrogen receptor β role in tumour suppression of triple negative breast cancer

Project description:Estrogen receptor β role in tumour suppression of triple negative breast cancer

| PRJEB33041 | ENA

Estrogen receptor β role in tumour suppression of triple negative breast cancer

2019-12-03 | E-MTAB-8055 | biostudies-arrayexpress

Caravagna2010 - Tumour suppression by immune system

Project description:Tumour suppression by immune system through stochastic oscillations GiulioCaravagnaa Albertod’Onofriob PaoloMilazzoa RobertoBarbutia https://doi.org/10.1016/j.jtbi.2010.05.013 Abstract The well-known Kirschner–Panetta model for tumour–immune System interplay [Kirschner, D., Panetta, J.C., 1998. Modelling immunotherapy of the tumour–immune interaction. J. Math. Biol. 37 (3), 235–252] reproduces a number of features of this essential interaction, but it excludes the possibility of tumour suppression by the immune system in the absence of therapy. Here we present a hybrid–stochastic version of that model. In this new framework, we show that in reality the model is also able to reproduce the suppression, through stochastic extinction after the first spike of an oscillation.

2024-09-02 | BIOMD0000000912 | BioModels

Deciphering molecular mechanisms of MEIS1-mediated prostate tumor suppression through RNAseq and ChIPseq - ChIPseq data

Project description:Deciphering molecular mechanisms of MEIS1-mediated prostate tumor suppression through RNAseq and ChIPseq - ChIPseq data

| PRJNA548800 | ENA

Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype - tumour ChIPseq data

Project description:Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype - tumour ChIPseq data

| PRJNA498223 | ENA

TRIM28 modulates progesterone and estrogen signaling in endometrium [mouseD35-PGR-ChIPseq-mm10]

Project description:TRIM28 modulates progesterone and estrogen signaling in endometrium [mouseD35-PGR-ChIPseq-mm10]

| PRJNA940832 | ENA

chipseq

Project description:chipseq data

| PRJEB39779 | ENA

Ionic immune suppression within the tumour microenvironment limits T cell effector function

Project description:Tumours progress despite being infiltrated by effector T cells. Tumour necrosis is associated with poor survival in a variety of cancers. Here, we report that that necrosis causes release of an intracellular ion, potassium, into the extracellular fluid of human and mouse tumours. Surprisingly, elevated extracellular potassium ([K+]e) was sufficient to profoundly suppress mouse and human T cell anti-tumour function. Elevations in [K+]e acted to acutely impair T cell receptor (TCR) dependent Akt-mTOR phosphorylation and effector function. Potassium mediated suppression of Akt-mTOR signalling and T cell effector function required intact activity of PP2A, a serine/threonine phosphatase. The suppressive effect mediated by elevated [K+]e required a T cell-intrinsic increase in intracellular potassium ([K+]i) and was independent of changes in plasma membrane potential (Vm). Finally, ionic reprogramming of tumour-specific T cells via over-expression of the voltage-gated potassium channel Kv1.3 lowered [K+]i and improved effector functions in vitro and in vivo, with this gain of function being dependent on intact channel function. Consequently, Kv1.3 T cell expression enhanced tumour clearance and the survival of melanoma-bearing mice. These results uncover a previously undescribed ionic checkpoint against T cell function within tumours and identify new strategies for cancer immunotherapy. RNA expression was measured by RNA-Seq on day 5 of cultures, maintained in individual biologial triplicates which were stimulated with immobilized anti-CD3/28 antibodies or kept in complete media (no stim) - with equivalent conditions treated with isotonic media containing elevated potassium.

2016-08-13 | E-GEOD-84996 | biostudies-arrayexpress

Deciphering molecular mechanisms of MEIS1-mediated prostate tumor suppression through RNAseq and ChIPseq

Project description:Deciphering molecular mechanisms of MEIS1-mediated prostate tumor suppression through RNAseq and ChIPseq

| PRJNA548792 | ENA